| COMPANY |
Apellis Pharmaceuticals, Inc. |
| COURT |
United States District Court for the District of Delaware |
| CASE NUMBER |
1:23-cv-00834 |
| JUDGE |
The Hon. Maryellen Noreika |
| CLASS PERIOD |
January 28, 2021 and July 28, 2023 |
| SECURITY TYPE |
Common Stock |
Case Background:
On August 2, 2023, Kessler Topaz Meltzer & Check, LLP filed a class action lawsuit on behalf of those who purchased or acquired Apellis Pharmaceuticals, Inc. ("Apellis") common stock between January 28, 2021 and July 28, 2023, both dates inclusive (the “Class Period”).
The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the company’s business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) the design of SYFOVRE’s clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) therefore, Defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis.
Current Status of Case:
On October 23, 2023, the Court appointed Lead Plaintiffs. This action is ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.